SyntekaBio Inc (226330) - Total Assets
Based on the latest financial reports, SyntekaBio Inc (226330) holds total assets worth ₩33.49 Billion KRW (≈ $22.70 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 226330 net asset value for net asset value and shareholders' equity analysis.
SyntekaBio Inc - Total Assets Trend (2017–2024)
This chart illustrates how SyntekaBio Inc's total assets have evolved over time, based on quarterly financial data.
SyntekaBio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
SyntekaBio Inc's total assets of ₩33.49 Billion consist of 28.7% current assets and 71.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 27.6% |
| Accounts Receivable | ₩187.20K | 0.0% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩450.39 Million | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how SyntekaBio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SyntekaBio Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SyntekaBio Inc's current assets represent 28.7% of total assets in 2024, a decrease from 50.9% in 2017.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2024, up from 0.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 20.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 1.0% of total assets.
SyntekaBio Inc Competitors by Total Assets
Key competitors of SyntekaBio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alcidion Group Ltd
AU:ALC
|
Australia | AU$115.63 Million |
|
DocCheck AG
XETRA:AJ91
|
Germany | €53.98 Million |
|
TRELLUS HEALTH LS -0006
F:85Q
|
Germany | €9.22 Million |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
|
Echoiq Ltd
AU:EIQ
|
Australia | AU$17.99 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$23.68 Million |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
|
Oneview Healthcare Plc
AU:ONE
|
Australia | AU$15.49 Million |
SyntekaBio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.20 | 1.00 | 40.04 |
| Quick Ratio | 0.20 | 1.00 | 40.04 |
| Cash Ratio | 0.00 | 0.97 | 0.00 |
| Working Capital | ₩-15.30 Billion | ₩-7.67 Million | ₩40.50 Billion |
SyntekaBio Inc - Advanced Valuation Insights
This section examines the relationship between SyntekaBio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.46 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -17.4% |
| Total Assets | ₩43.71 Billion |
| Market Capitalization | $39.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values SyntekaBio Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: SyntekaBio Inc's assets decreased by 17.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SyntekaBio Inc (2017–2024)
The table below shows the annual total assets of SyntekaBio Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩43.71 Billion ≈ $29.63 Million |
-17.39% |
| 2023-12-31 | ₩52.92 Billion ≈ $35.86 Million |
-4.98% |
| 2022-12-31 | ₩55.69 Billion ≈ $37.74 Million |
-17.96% |
| 2021-12-31 | ₩67.88 Billion ≈ $46.00 Million |
+51.59% |
| 2020-12-31 | ₩44.78 Billion ≈ $30.35 Million |
-6.61% |
| 2019-12-31 | ₩47.95 Billion ≈ $32.49 Million |
+296.00% |
| 2018-12-31 | ₩12.11 Billion ≈ $8.21 Million |
+383.70% |
| 2017-12-31 | ₩2.50 Billion ≈ $1.70 Million |
-- |
About SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more